Tesamorelin 6mg/Ipamorelin 3mg/CJC-1295 no Dac 3mg
Janoshik
Batch TICA-CA-26G-12
- Tesamorelin
- 6.74 mg
- Ipamorelin
- 3.61 mg
- CJC-1295 (mod GRF 1-29)
- 3.76 mg
Tesamorelin 6mg/ Ipamorelin 3mg/ CJC-1295 no Dac 3mg
Growth Hormone Secretagogue Blend
Also known as Tesamorelin 6mg + Ipamorelin 3mg + CJC-1295 No DAC 3mg
Triad-GH is a research blend supplying tesamorelin, ipamorelin, and CJC-1295 (No DAC) in a single vial.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within the United States. It is not approved by the FDA for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable U.S. federal, state, and local regulations.
Triad-GH is a research blend supplying tesamorelin, ipamorelin, and CJC-1295 (No DAC) in a single vial.
Each component is separately characterized in growth-hormone axis research; the combination itself has no published literature.
Triad-GH combines two GHRH-analogue components with a selective ghrelin-receptor secretagogue. Tesamorelin is a growth-hormone-releasing factor analogue characterized in clinical research. CJC-1295 without the drug affinity complex is a modified GHRH(1-29) analogue. Ipamorelin is described as the first selective growth-hormone secretagogue, acting at GHS-R1a.
Combining GHRH-pathway and ghrelin-pathway agents in one vial is a formulation choice. References below come from the component literature.
The components entered research separately: GHRH analogues through work on growth-hormone-releasing factor from the 1980s, and ipamorelin through selective secretagogue screening in the 1990s.
The blend has no separate development history and is a supplier formulation.
Research relevant to Triad-GH is the sum of its components: GHRH-receptor pharmacology, ghrelin-receptor secretagogue activity, and GH/IGF-1 axis regulation. No study has evaluated this specific three-component combination.
2 of the 4 areas below are addressed directly by a paper cited on this page.
GHRH-analogue pharmacology
Addressed on this page by Falutz 2010. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Falutz, J. et al. (2010) — Effects of tesamorelin (TH9507), a growth hormone–releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
Ghrelin-receptor (GHS-R1a) secretagogue models
Addressed on this page by Raun 1998. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
- Raun, K. et al. (1998) — Ipamorelin, the first selective growth hormone secretagogue.
GH/IGF-1 axis regulation research
No paper cited on this page reports on axis or regulation. This heading marks where Tesamorelin 6mg/ Ipamorelin 3mg/ CJC-1295 no Dac 3mg is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
Combined-pathway formulation frameworks
No paper cited on this page reports on combined or formulation. This heading marks where Tesamorelin 6mg/ Ipamorelin 3mg/ CJC-1295 no Dac 3mg is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 5 primary papers published between 1998 and 2010 — a limited but non-trivial record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Tesamorelin 6mg/ Ipamorelin 3mg/ CJC-1295 no Dac 3mg is frequently listed as a peptide by suppliers in this market. It is not one. The structure published on this page is the compound's actual chemistry, and research on it should be read against its own class rather than against peptide literature.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for Tesamorelin 6mg/ Ipamorelin 3mg/ CJC-1295 no Dac 3mg, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
Tesamorelin 6mg/ Ipamorelin 3mg/ CJC-1295 no Dac 3mg is commonly described online in connection with muscle growth, fat loss and improved recovery. In the research literature the same compound is filed under GHRH-analogue pharmacology, ghrelin-receptor (GHS-R1a) secretagogue models and GH/IGF-1 axis regulation research.
Of the 5 papers cited on this page, published between 1998 and 2010, 2 report work in human participants — Falutz 2010 and Falutz 2010. Human data for a molecule is not the same as evidence for material supplied as a research compound: published trials use pharmaceutical-grade product under medical supervision at defined doses. What is established for the material sold here is its measured purity and content per lot.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
The lot code printed on the vial matches the code on the certificate for Tesamorelin 6mg/ Ipamorelin 3mg/ CJC-1295 no Dac 3mg. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy Tesamorelin 6mg/ Ipamorelin 3mg/ CJC-1295 no Dac 3mg in the United States through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
- Lyophilized storage
- −20 °C long-term; stable at room temperature in transit
- After reconstitution
- 2–8 °C
- Light
- Protect from UV and direct light
- Freeze-thaw
- Avoid repeated cycles
- Vehicle
- Solvent selection depends on the compound; consult the published literature
- Format
- Lyophilized powder
Tesamorelin 6mg/ Ipamorelin 3mg/ CJC-1295 no Dac 3mg is supplied as lyophilized powder. It is not a peptide, and solvent behaviour follows from its own chemistry rather than from the aqueous-vehicle conventions that apply to peptide material — the published literature for this compound is the reference for solvent selection, not a general peptide protocol.
Dry storage below freezing and protection from light are the general controls. As with any lyophilized material, the powder frequently sits as a thin film at the base of the vial and is easy to mistake for an empty vial before inspection.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
- 1 × sealed glass vial in the strength selected (12mg / Single Vial, 12mg / 5-Pack, 12mg / 10-Pack available), batch-labelled
- The batch-linked Certificate of Analysis for the exact lot shipped
- Discreet outer packaging with no product names on the exterior
- FedEx, tracked, typically 1–3 business days domestically
- Bacteriostatic water or any other reconstitution vehicle
- Syringes, needles or filters
- Dosing, administration or protocol guidance of any kind
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of Triad-GH. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Effects of tesamorelin (TH9507), a growth hormone–releasing factor analogue, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extension.
PubMedEffects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab 95(9):4291–4304.
PubMedIpamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats.
PubMedProlonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of growth hormone–releasing hormone, in healthy adults.
PubMedRelated
You May Also Like
TB-500 Fragment 17-23 is the seven-residue actin-binding region of thymosin beta-4, studied in research on tissue repair and cell migration.
From$44.99
Dual peptide complex studied for actin signaling, tissue regeneration pathways, and recovery system research
From$59.99
Wolverine+ is a research blend supplying cartalax, BPC-157, and TB-500 in a single vial.
From$99.99
Coremend is a research blend combining TB-500 (thymosin beta-4 fragment), BPC-157, and the tripeptide KPV in a single preparation, studied for converging tissue-repair and inflammatory-signaling pathways.
From$220.00